Stock Track | ImmunityBio, Inc. Soars 23.73% Intraday on FDA Regulatory Progress for Anktiva

Stock Track01-20

ImmunityBio, Inc. (IBRX) saw its stock surge 23.73% during the intraday session on Tuesday, reflecting strong investor optimism.

The rally follows positive developments in the company's regulatory discussions with the FDA regarding Anktiva, its drug candidate for Bcg-unresponsive papillary bladder cancer. ImmunityBio provided updates on its Type B End-of-Phase meeting and potential resubmission pathways, which have bolstered confidence in the drug's approval prospects.

Analysts have maintained bullish ratings on the stock, with D. Boral Capital and Piper Sandler reiterating their Buy and Overweight positions, respectively, further supporting the positive sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150440541?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150440541","market":"us","top_or_hot":-1,"title":"Stock Track | ImmunityBio, Inc. Soars 23.73% Intraday on FDA Regulatory Progress for Anktiva","media":"Stock Track","content":"<p>ImmunityBio, Inc. (IBRX) saw its stock surge 23.73% during the intraday session on Tuesday, reflecting strong investor optimism.</p><p>The rally follows positive developments in the company's regulatory discussions with the FDA regarding Anktiva, its drug candidate for Bcg-unresponsive papillary bladder cancer. ImmunityBio provided updates on its Type B End-of-Phase meeting and potential resubmission pathways, which have bolstered confidence in the drug's approval prospects.</p><p>Analysts have maintained bullish ratings on the stock, with D. Boral Capital and Piper Sandler reiterating their Buy and Overweight positions, respectively, further supporting the positive sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio, Inc. Soars 23.73% Intraday on FDA Regulatory Progress for Anktiva</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio, Inc. Soars 23.73% Intraday on FDA Regulatory Progress for Anktiva\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-20 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (IBRX) saw its stock surge 23.73% during the intraday session on Tuesday, reflecting strong investor optimism.</p><p>The rally follows positive developments in the company's regulatory discussions with the FDA regarding Anktiva, its drug candidate for Bcg-unresponsive papillary bladder cancer. ImmunityBio provided updates on its Type B End-of-Phase meeting and potential resubmission pathways, which have bolstered confidence in the drug's approval prospects.</p><p>Analysts have maintained bullish ratings on the stock, with D. Boral Capital and Piper Sandler reiterating their Buy and Overweight positions, respectively, further supporting the positive sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1150440541","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150440541","pubTimestamp":1768919782,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (IBRX) saw its stock surge 23.73% during the intraday session on Tuesday, reflecting strong investor optimism.The rally follows positive developments in the company's regulatory...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio，Inc.盘中飙升23.73%，因FDA对Anktiva的监管进展","themeId":"c6432e252784cc64192d8c0a1d7cc58c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (IBRX) saw its stock surge 23.73% during the intraday session on Tuesday, reflecting strong investor optimism.The rally follows positive developments in the company's regulatory discussions with the FDA regarding Anktiva, its drug candidate for Bcg-unresponsive papillary bladder cancer. ImmunityBio provided updates on its Type B End-of-Phase meeting and potential resubmission pathways, which have bolstered confidence in the drug's approval prospects.Analysts have maintained bullish ratings on the stock, with D. Boral Capital and Piper Sandler reiterating their Buy and Overweight positions, respectively, further supporting the positive sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150440541","isCrawlerRequest":true}